TP53 and acute myeloid leukemia: AML‐MRC patients with TP53 double/multi‐hit had no significant differences in OS (HR 1.10, 95% CI 0.60–2.01, p = 0.76) and EFS (HR 1.20, 95% CI 0.66–2.19, p = 0.55) compared to patients with TP53 single‐hit (Figure 3C,D).